National Institute of Biological Sciences, Beijing

Evopoint Biosciences Co., Ltd.

Sinomab Bioscience Limited

Suzhou Sinovent Pharmaceuticals Co., Ltd.

Shaoqiang Huang

Xi Chen

Yuchuan Wu

Yonghan Hu

Xiao Xi Liu

Xiaodong Wang

Zhiyuan Zhang

Jianguang Han

Li Li

Zhaolan Zhang

Xian Jiang

Lei Liu

Xin Li

Bo Yan

Dongdong Wu

Wei Peng

Huayi Wang

Jinlian Zhu

Bin Huang

Linhai Qu

Zhi Huang

Weiye Cao

Jun Xian

Xiao Liu

The present invention provides a novel EZH2 inhibitor compound represented by formula (I) and a use of the inhibitor compound in preventing or treating a disease mediated by EZH2.

Polysubstituted benzene compound and preparation method and use thereof

The invention provides compounds that are inhibitors or covalent modifiers of succinate dehydrogenase subunit B (SDHB) and/or inhibitors of apoptosis, and pharmaceutically acceptable salts, hydrates and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof with an effective amount of the compound or composition.

Apoptosis inhibitors

The invention provides compounds that inhibit human MLKL, and pharmaceutically acceptable salts, hydrates and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof with an effective amount of the compound or composition.

MLKL inhibitors

Provided are a heterocyclic compound, a preparation method and the use thereof in medicine, and particularly involved are a heterocyclic compound for preventing and/or treating hypemricemia and gout, a preparation method and the use thereof in medicine. In particular, provided are a compound as shown in formula (I) and/or formula (II) or a tautomer thereof and a pharmaceutically acceptable salt thereof, a preparation method therefor and a method and the use thereof for treating hypemricemia and gout. 

Heterocyclic compound, preparation method and use thereof in medicine

Disclosed is a new crystal form of a 5-aminopyrazole carboxamide compound as shown in Formula (I). Also disclosed are a preparation method for said crystal form of said compound, a pharmaceutical composition of said crystal form of said compound, and uses thereof. 

Crystal form I of a 5-aminopyrazole carboxamide compound as BTK inhibitor

Provided are a &#x3b2;-lactamase inhibitor of formula (I), or an ester, a stereoisomer or a pharmaceutically acceptable salt thereof, and a method of preparing the same. Further provided is a pharmaceutical composition comprising the &#x3b2;-lactamase inhibitor of formula (I), or the ester, the stereoisomer or pharmaceutically acceptable salt thereof. In addition, the present invention relates to a method for treating diseases caused by bacterial infection, which comprises administering the &#x3b2;-lactamase inhibitor of formula (I), or the ester, the stereoisomer or the pharmaceutically acceptable salt thereof to a patient or a subject in need. 

&#x3b2;-lactamase inhibitor and use thereof

Growing community of inventors

Beijing, China

Shaoqiang Huang